Biotech - Oncology
•324 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (324)
%
| Company | Market Cap | Price |
|---|---|---|
|
Strategic focus on oncology collaborations and immunology-related antibody/discovery work.
|
$59.46M |
N/A
|
|
Company focuses on oncology, specifically solid tumors (e.g., glioblastoma).
|
$59.44M |
$3.25
-2.98%
|
|
Company is a clinical-stage oncology biotech focused on immunotherapy and targeted cancer therapies.
|
$57.88M |
$1.57
-7.10%
|
|
OSTX's lead product OST-HER2 is an oncology immunotherapy based on a Listeria platform, directly constituting a cancer treatment product.
|
$55.91M |
$1.99
-5.24%
|
|
Company focus and lead program in oncology (solid tumors) with iNKT cell therapy and combination trials.
|
$55.80M |
$14.00
-4.24%
|
|
Company's biotech assets focus on oncology/hematologic malignancies.
|
$55.17M |
$15.70
-1.94%
|
|
Kronos Bio's core activity centers on oncology therapeutics and transcription-targeted oncology programs, aligning with Biotech - Oncology.
|
$53.65M |
$0.88
+1.49%
|
|
ABVC's pipeline includes oncology-focused plant-derived therapeutics and cancer programs (e.g., ABV-1519 for NSCLC), aligning with Biotech - Oncology.
|
$50.99M |
$3.04
-7.03%
|
|
The company positions itself as Biotech - Oncology, focusing on cancer therapies.
|
$50.76M |
$1.02
+11.90%
|
|
BioAtla is a biotechnology company focused on oncology therapies, fitting Biotech - Oncology.
|
$50.68M |
$0.87
-17.38%
|
|
Telomir-1's preclinical oncology results place the company in the biotech oncology space.
|
$49.11M |
$1.65
-7.82%
|
|
Core oncology specialization with solid-tumor engineered T-cell therapies for sarcoma indications.
|
$49.11M |
$0.18
-9.80%
|
|
Oncology-focused cell therapies with CNTY-101 and related CAR-iT/iNK programs position Century within cancer immunotherapy.
|
$49.00M |
$0.57
-5.22%
|
|
INKmune NK-cell therapy platform targets oncology (solid tumors), representing a direct cancer therapy product line.
|
$48.97M |
$2.08
-1.18%
|
|
Nu.Q Cancer represents human oncology diagnostics, placing VolitionRx in the Biotech - Oncology space.
|
$47.81M |
$0.46
-10.75%
|
|
Karyopharm is a biotechnology company focused on oncology therapies, anchored by its cancer‑drug selinexor and SINE technology.
|
$47.52M |
$5.50
-6.94%
|
|
Lantern Pharma's core assets and clinical pipeline are oncology-focused, mapping to Biotech - Oncology.
|
$46.81M |
$4.34
-7.26%
|
|
Company's focus is oncology-focused biopharma products and radiopharmaceutical development.
|
$46.48M |
$1.49
-1.97%
|
|
Company operates in oncology-focused biotech, aligning with the Biotech - Oncology investable theme.
|
$46.41M |
$7.03
-5.64%
|
|
Company focuses on Biotech oncology therapeutics and ADCs, a core oncology biotech business.
|
$46.06M |
$9.24
+1.43%
|
|
SNTI's core focus is oncology with immunotherapies and cell-based therapies, aligning with Biotech - Oncology.
|
$44.08M |
$1.69
-11.05%
|
|
Xilio focuses on oncology immunotherapies (vilastobart and XTX301), fitting Biotech - Oncology.
|
$43.64M |
$0.84
-5.31%
|
|
Company directly develops oncology-focused immunotherapies and platforms (Versamune HPV, PDS01ADC, Versamune MUC1) used to treat HPV-related cancers.
|
$43.30M |
$0.95
-5.27%
|
|
VP-315 for basal cell carcinoma is an oncology program, supporting a Biotech - Oncology investment theme.
|
$43.19M |
$4.67
+2.41%
|
|
FibroGen's oncology-focused pipeline (FG-3246) places the company in the oncology biotech space.
|
$42.64M |
$10.55
-3.74%
|
|
Biotech - Oncology category given RDGL's focus on cancer therapies and oncology applications.
|
$40.84M |
$0.09
+0.90%
|
|
LAVA Therapeutics develops oncology therapies around its platform, placing it squarely in Biotech - Oncology.
|
$40.76M |
$1.55
+0.65%
|
|
Oncology programs are in early-stage preclinical development using the boron platform, representing a core strategic expansion area.
|
$39.23M |
$1.30
+2.36%
|
|
Directly focused on oncology therapeutics (amezalpat and TPST-1495) as small-molecule cancer drugs.
|
$38.30M |
$10.40
-2.07%
|
|
Dissolvable microneedle drug-delivery platform for skin cancer (Dermato-oncology) and the GnRH antagonist Teverelix for prostate cancer place Medicus Pharma squarely in oncology-focused biotechnology.
|
$37.07M |
$2.48
-3.13%
|
|
Preclinical oncology-focused biopharmaceutical company developing a high-affinity anti-CD47 antibody.
|
$36.68M |
$1.41
-9.03%
|
|
IO Biotech operates in oncology-focused biotechnology and its lead products are cancer vaccines.
|
$36.37M |
$0.55
-4.81%
|
|
OT-101 is an RNA-targeted/antisense oncology therapeutic in late-stage clinical development.
|
$35.83M |
$0.09
-9.09%
|
|
Mural Oncology is focused on developing oncology immunotherapies and engineered cytokine therapeutics (nemvaleukin and related programs).
|
$35.75M |
$2.07
-0.48%
|
|
OnKure Therapeutics is a biotechnology company focused on oncology with a pipeline of targeted cancer therapies (lead PI3Kα mutant inhibitor).
|
$35.13M |
$2.60
+0.58%
|
|
Biotech - Oncology focus via MAIT cell immunotherapy for solid tumors.
|
$34.35M |
$4.39
-2.55%
|
|
Legacy oncology assets (LipoMedix, Cornerstone) position the company within oncology-focused Biotech.
|
$33.38M |
$1.34
-1.47%
|
|
CEL-SCI develops oncology-focused immunotherapy products, with Multikine as the lead candidate for cancer treatment.
|
$31.77M |
$10.47
+2.25%
|
|
Exicure's core biotechnology focus is on oncology, anchored by the GPCR USA lead asset (GPC-100.00).
|
$31.27M |
$4.95
-13.91%
|
|
Pipeline includes oncology-focused therapies, representing biotech oncology activity.
|
$30.76M |
$1.07
-8.15%
|
|
Company focus is oncology diagnostics, including blood cancer applications.
|
$28.79M |
$19.04
-7.65%
|
|
Boundless Bio operates as a biotech oncology company developing cancer therapies targeting ecDNA, fitting the Biotech - Oncology category.
|
$27.53M |
$1.23
-0.81%
|
|
Leap's core assets are antibody-based oncology therapies, placing it squarely in Biotech - Oncology.
|
$26.46M |
$0.64
-4.13%
|
|
Lead CNS cancer programs place PSTV in the Biotech - Oncology space.
|
$24.42M |
$0.72
-7.07%
|
|
Allarity's lead therapy stenoparib targets oncology indications (PARP/WNT inhibitor) representing its core Biotech - Oncology business.
|
$24.28M |
$1.61
-8.52%
|
|
CytoMed Therapeutics operates in oncology-focused biotech and develops cancer immunotherapies.
|
$23.77M |
$2.06
-8.44%
|
|
Company focuses on oncology diagnostics and prognostics, fitting Biotech - Oncology.
|
$23.64M |
$1.47
+2.85%
|
|
BE-Smart diagnostic test centers on oncology/esophageal cancer detection, aligning with Biotech - Oncology.
|
$21.85M |
$0.53
+1.29%
|
|
HT-001 and HT-KIT are oncology-focused assets, placing Hoth Therapeutics squarely in Biotech - Oncology.
|
$20.87M |
$1.58
-5.39%
|
|
Lisata Therapeutics operates in oncology biotech with certepetide as its lead cancer therapy.
|
$20.38M |
$2.37
|
|
Company is a biotech focused on oncology therapeutic development.
|
$20.27M |
$18.43
|
|
Propanc Biopharma's core offering is a cancer therapy (PRP) in preclinical development, aligning with Biotech - Oncology.
|
$20.09M |
$1.73
-6.99%
|
|
Company develops oncology-focused therapies (ENV-105, KROS candidates).
|
$19.55M |
$1.16
-12.12%
|
|
Legacy oncology assets narazaciclib and rigosertib are being advanced via partnerships, placing the company in Biotech - Oncology.
|
$16.75M |
$3.01
-2.27%
|
|
PV-10 is Provectus' lead oncology therapeutic developed from Rose Bengal Sodium (RBS).
|
$16.11M |
$0.08
+0.93%
|
|
Emavusertib is an oncology asset, representing Curis's core product focus in cancer therapeutics.
|
$15.90M |
$1.52
-6.17%
|
|
NXTC operates in Biotech - Oncology as its primary disease focus and target.
|
$15.54M |
$6.65
+5.59%
|
|
Biotech - Oncology reflects a stated biotech arm (Fuse Biotech) with potential oncology-focused therapies or programs.
|
$15.41M |
$0.24
|
|
OnkosXcel's BXCL701 represents an immuno-oncology asset, placing the company in oncology biotech development.
|
$15.32M |
$2.53
-3.80%
|
|
LB-100 is Lixte's lead oncology drug (PP2A inhibitor) and the core product being developed for cancer indications.
|
$14.28M |
$5.32
-3.80%
|
|
IBIO is developing oncology-focused antibody therapies and bispecific antibodies for cancer targets.
|
$14.19M |
$0.81
-0.30%
|
|
Lead asset solnerstotug is an oncology monoclonal antibody therapy targeting VISTA.
|
$14.19M |
$11.26
-5.06%
|
|
Company is advancing an oncology-focused biotech platform (FHAB) with lead asset SON-1010, making oncology the core direct business line.
|
$13.96M |
$4.41
-6.96%
|
|
The licenses and internal programs include oncology-focused drug assets, indicating a cancer therapeutics focus.
|
$13.56M |
$1.44
-4.64%
|
|
Biotech focus in oncology tied to KRAS gene activities.
|
$13.32M |
$0.12
|
|
LYMPHIR is an FDA-approved targeted immunotherapy for CTCL (cancer), representing a core oncology biotech product.
|
$12.66M |
$1.23
-6.11%
|
|
UNO oncology program via Beyond Cancer places NO-based therapy within an oncology pipeline.
|
$11.78M |
$2.54
-5.58%
|
|
Biotechnology segment with oncology-focused programs and pipeline support.
|
$11.75M |
$1.29
-4.30%
|
|
Company focuses on oncology therapeutics and is actively developing immuno-oncology therapies.
|
$11.43M |
$1.01
-4.72%
|
|
Company operates in the oncology biotech space, focusing on cancer diagnostics.
|
$11.13M |
$4.08
-7.06%
|
|
Bolt Biotherapeutics is a clinical-stage oncology biotech developing immunotherapies, aligning with Biotech - Oncology.
|
$11.12M |
$5.80
-1.60%
|
|
Directly involved in oncology-focused cellular therapies as a platform for CAR-Macrophages used to treat solid tumors.
|
$10.90M |
$0.24
-6.09%
|
|
OSR Holdings' VAXIMM AG focuses on oral immunotherapies for cancer, aligning with Oncology-focused biotechnology.
|
$10.69M |
$0.55
-9.02%
|
|
PHIO develops innovative oncology therapies leveraging IO and immune modulation in cancer, aligning with Biotech - Oncology.
|
$10.57M |
$2.20
-7.09%
|
|
Direct focus on oncology programs (PDAC) with motixafortide data supporting oncology indications.
|
$9.38M |
$3.91
-5.10%
|
|
Biotech oncology focus via VitaGuard MRD and related diagnostics capabilities.
|
$9.32M |
$5.19
-3.71%
|
|
Aptorum's pipeline includes oncology-focused therapeutics (e.g., SACT-1) in Phase 1, establishing Biotech - Oncology as a core segment.
|
$9.08M |
$1.66
-30.83%
|
|
Directly develops oncology drugs as a biotech company focused on cancer therapeutics.
|
$8.93M |
$0.20
|
|
Directly focused on oncology therapeutics and cancer targets (miR-10b) within a biotech/oncology pipeline.
|
$8.81M |
$10.56
-1.45%
|
|
PAVmed's biopharma expansion includes oncology-focused assets, i.e., Biotech - Oncology.
|
$8.61M |
$0.49
-13.83%
|
|
Business focus in oncology within the biotech space, including biobank assets and data-driven discovery platforms.
|
$8.53M |
$14.32
+1.31%
|
|
Collaborations targeting oncology via protein/peptide-based approaches.
|
$8.46M |
$0.00
-20.00%
|
|
Gedeptin represents an oncologic therapy, placing GeoVax in the Biotech - Oncology space.
|
$8.44M |
$0.56
-7.43%
|
|
Direct focus on oncology therapies and cancer immunotherapy platforms.
|
$8.21M |
$0.35
|
|
Company pipeline includes oncology-focused immunotherapy programs (HS1940, HS3215) and related cancer therapeutics.
|
$7.93M |
$2.98
-7.45%
|
|
Directly focused on oncology biotech development (Biotech - Oncology) with DDR pathway inhibitors.
|
$7.85M |
$1.42
-5.33%
|
|
Linebacker platform primarily targets oncology indications via electrophilically enhanced polyphenol compounds; aligns with biotech oncology category.
|
$7.69M |
$0.64
+0.47%
|
|
CBIO directly develops oncology-focused biologic therapies, aligning with the Biotech - Oncology category.
|
$7.32M |
$11.35
-6.81%
|
|
Biotech company focused on oncology, with a pipeline in radiopharmaceuticals and cancer-targeted therapies.
|
$7.13M |
$4.64
-3.73%
|
|
Proprietary oncology programs (K1.1 mRNA) place the company in oncology-focused biotech development.
|
$7.06M |
$1.55
-6.63%
|
|
Pipeline includes cancer-focused CAR T programs and oncolytic virus therapy targeting tumors, establishing a primary oncology focus.
|
$6.92M |
$1.56
-0.95%
|
|
PMCB's core offering is oncology cell-based therapy using the Cell-in-a-Box encapsulation platform (CypCaps) to target cancer, notably LAPC.
|
$6.86M |
$1.00
|
|
Cancer diagnostic initiatives place Ludwig within Biotech - Oncology as a focus area.
|
$6.79M |
$0.04
|
|
Company's lead asset Annamycin is an oncology therapeutic, making Moleculin a cancer-focused biotech with direct drug development in oncology.
|
$6.52M |
$0.46
-5.78%
|
|
Operates as a biotech company with an oncology-focused pipeline (personalized cancer vaccine EVX-01) and cancer/immunology therapeutics.
|
$6.39M |
$5.90
-9.65%
|
|
The company operates in oncology immunotherapies, focusing on cancer indications with gamma-delta T cell approaches.
|
$6.35M |
$2.10
-7.08%
|
|
HCWB is developing innovative cancer immunotherapies, placing the company in Biotech - Oncology.
|
$5.84M |
$4.06
-10.77%
|
|
Directly develops oncology therapeutics (antineoplastons), fitting Biotech - Oncology.
|
$5.65M |
$0.04
|
|
Company focuses on intratumoral immuno-oncology with INT230-6.00; oncology-focused biotech developing cancer therapies.
|
$5.61M |
$0.30
-17.43%
|
|
Reiterates oncology focus; included for emphasis on cancer therapy dimension.
|
$5.58M |
$0.75
-3.55%
|
Showing page 3 of 4 (324 total stocks)
Loading industry metrics...
Loading comparison data...
